Abbott Adding Nutritional For Consumers Using Type 2 Diabetes, Weight Management Drugs

Ensure and Glucerna brand and other adult product sales up 12.5% to account for $1.05bn of $2.04bn in total Q4 nutritionals sales; full-year adult product sales up 6.2%, accounting for $4.2bn of Abbott’s $8.15bn in total nutritionals sales.

• Source: Shutterstock

Adult products led Abbott ’s nutritional business sales growth in 2023 and likely will become a stronger driver in 2024 with the launch of a formulation for people using medications rapidly growing in popularity with the addition of a weight loss indication.

Sales of Abbott’s Ensure and Glucerna brands accounted for $1.05bn of the firm’s $2.04bn in total nutritionals sales for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Nestlé Puts VMS Value Brands On Chopping Block To Focus On Premium Market

 
• By 

Nature’s Bounty, Osteo Bi-Flex and Puritan’s Pride are among the dietary supplement brands under strategic review by Nestle as the firm shifts its focus to the premium end of the market.

BioGaia Takes Probiotics To Netherlands For First Time

 
• By 

Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By 

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Dermapharm Seeks To Put Stop To Spanish Slide

 
• By 

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

More from Business

Over The Counter: Seizing The GLP-1 Wellness Opportunity, With Kerry Group’s Mathieu Millette

 
• By 

HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

People In US Consumer Health News: Bayer North America Treasurer Takes On CFO Role, Too

 

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.